Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

[1] Faivre S(2007)Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov. 6 734-745

[2] Demetri G(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338

[3] Sargent W(2009)NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw 7 618-630

[4] Demetri GD(2009)Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590

[5] van Oosterom AT(2015)Alternate sunitinib schedules in patients with metastatic renal cell carcinoma Ann Oncol 26 1300-1304

[6] Garrett CR(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124

[7] Motzer RJ(2009)Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 4068-4075

[8] Agarwal N(2012)Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 1371-1377

[9] Beard C(2009)Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 1959-1968

[10] Motzer RJ(2010)Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 357-371

[1] Faivre S(2007)Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov. 6 734-745

[2] Demetri G(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338

[3] Sargent W(2009)NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw 7 618-630

[4] Demetri GD(2009)Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590

[5] van Oosterom AT(2015)Alternate sunitinib schedules in patients with metastatic renal cell carcinoma Ann Oncol 26 1300-1304

[6] Garrett CR(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124

[7] Motzer RJ(2009)Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 4068-4075

[8] Agarwal N(2012)Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 1371-1377

[9] Beard C(2009)Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 1959-1968

[10] Motzer RJ(2010)Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 357-371